Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jan 15, 2010

NEW YORK (GenomeWeb News) — Klaus Lindpaintner has been hired by Strategic Diagnostics as VP of research and development and CSO.

Lindpaintner, who was director of Roche Molecular Medicine Laboratories and was global head of its policy and external affairs, will begin in his new position in February.


Intrexon has appointed Thomas Goralski to be president of its UltraVector Division and senior VP of the corporation.

Goralski has worked in various leadership roles at Incyte Genomics, Perlegen Sciences, and at Expression Analysis. He will be based at Intrexon’s Blacksburg, Va. production facility.


Craig Christianson has left his position as licensing director at the Wisconsin Alumni Research Foundation to become general counsel at Promega.

WARF said that Michael Falk will serve as interim licensing director while the organization’s board of directors and staff work to permanently fill the position.


Population Diagnostics has appointed Peggy Eis to be its chief technology officer, a role in which she will work to scale up the firm’s biomarker discovery platform.

Eis previously was senior director of genome variation at Roche NimbleGen, and was head of the CGH microarray business at NimbleGen. She also led DNA and RNA detection development at Third Wave Technologies.


Bind Biosciences has named Scott Minick to be company president and CEO.

Minick formerly was a managing director at Arch Venture Partners, which is a major investor in Bind. He also was president and COO of Sequus Pharmaceuticals/Liposome Technology.


Protagen has appointed Peter Shulze-Knappe and Martin Bluggel to serve on its executive board, and Thomas Schweins to its supervisory board.

Schulze-Knappe, who will take over operations for the Diagnostics business unit, formerly was CSO at Proteome Sciences.

Bluggel, who is company co-founder and COO, will join the board and manage the Protein Services business unit.

Schweins is a member of the executive committee at Qiagen and he has held jobs in the Pharma/Health Care Unit of Boston Consulting Group.


Bruker has appointed Urban Faeh to be president of its Bruker Optics division, effective immediately.

Faeh will also take over the role of managing director of Bruker Optik in Germany at a later date, the company said.


DNAVision has appointed Laurent Alexandre to serve as president and chairman of the board at DNAVision SA, where he will lead the company’s personalized medicine and consumer genomics business.

Alexandre founded two French public companies, Medcost and Doctissimo, and has participated in the development of a Benefit, a clinical research company.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.